Xinuo Wei: 2025 Revenue Growth of 8.9% to 2.16 Billion Yuan, Multiple In-Development Products Receive Clinical Trial Approvals

Recently, XinNuoWei announced its 2025 annual report. The company’s operating revenue was 2.16 billion yuan, an increase of 8.9% year-over-year; net profit attributable to shareholders was a loss of 241 million yuan, a decrease of 548.8%; non-recurring net profit attributable to shareholders was a loss of 294 million yuan, a decrease of 795.3%; net operating cash flow was -196 million yuan, an increase of 84.2%.

In the 2025 annual report, the company stated that there were no significant adverse changes in its business operations. The company continued to increase R&D investment, with total R&D expenses reaching 1.036 billion yuan, an increase of 194 million yuan or 23.01% compared to the previous year. During the reporting period, the company made significant progress in the field of innovative biopharmaceuticals, with several pipeline products receiving clinical trial approval, including 9 products approved for the first time in China and 4 products approved by the U.S. FDA.

In the biopharmaceutical and functional raw materials sectors, the company actively promoted product research, development, and commercialization, especially in cutting-edge technology platforms such as antibody drugs, ADCs, and mRNA vaccines. Despite market pressures, the company maintained its core competitiveness and strengthened its position in the functional raw materials market. During the reporting period, the sales of caffeine-based products also continued to increase.

(XinNuoWei Announcement)

(Editors: Yang Yan, Lin Chen)

Keywords: Healthcare